America's Poison Centers reported nearly 3,000 calls this year involving the weight loss drug semaglutide—a 15-fold increase since 2019, according to CNN.
Dec 14, 2023
0
0
The biggest health and nutrition story of 2023 was arguably the exploding popularity of prescription medications to treat obesity, a chronic disease that affects more than four in 10 U.S. adults.
Dec 14, 2023
0
0
In 1976, a Swedish pathologist, C.G Lindström, published a paper describing a colonic anomaly. Through his microscope, he noted that part of the large intestinal wall of one of his patients was thickened. The patient, whose ...
Dec 13, 2023
0
0
UK organizations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law, reveals an investigation published by The ...
Dec 13, 2023
0
12
The World Health Organization (WHO) sees obesity as one of the greatest challenges for public health in the 21st century. The Austrian Institute for Health Technology Assessment (AIHTA) has now examined group programs offered ...
Dec 13, 2023
0
4
More than 70 kidney transplants were performed every day in the United States last year. Rachel Watson wanted to be one of the donors, but was told she didn't qualify, at first.
Dec 10, 2023
0
18
Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective. Importantly, the data also reveals how anti-obesity drugs like Ozempic, ...
Dec 8, 2023
0
2
Weight-inclusive health care means a focus on better health with no weight loss required.
Dec 7, 2023
0
0
The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday.
Dec 6, 2023
0
3
Wegovy, Mounjaro, Ozempic... These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?
Dec 4, 2023
0
0
